Global Catheters Market to Reach $45.99 Billion by 2030

The global catheters market is projected to grow from USD 30.53 billion in 2025 to USD 45.99 billion by 2030, registering a CAGR of 8.5% during the forecast period. The report, spanning 455 data tables and 67 figures across 415 pages, provides a comprehensive analysis of market dynamics, segmentation, and regional trends shaping the industry. Amid the global shift toward precision medicine and minimally invasive care, the Catheters Market is gaining strong momentum as a critical enabler of modern interventional procedures across cardiovascular, urology, and neurology domains.

Download PDF Brochure:-  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6247803

What Is Fueling the Growth of the Catheters Market?

The increasing adoption of minimally invasive and image-guided procedures is a primary driver of market expansion. Why is this shift accelerating? Healthcare providers are prioritizing procedures that reduce patient trauma, shorten recovery times, and improve clinical outcomes.

Technological innovation is further transforming catheter-based interventions. Advanced features such as pressure-sensitive and steerable catheters, drug-coated devices, and infection-resistant coatings are enhancing procedural precision and reducing complication risks. At the same time, the integration of AI-based navigation systems and real-time imaging—especially in interventional cardiology and neurology—is enabling clinicians to perform complex procedures with greater accuracy.

Additionally, the development of hybrid catheter laboratories and advanced surgical suites in high-end healthcare facilities is expanding the scope of catheter-based treatments. Combined with the rising prevalence of chronic and lifestyle-related diseases, these factors are driving sustained demand and shaping long-term market growth.

Which Segment Dominates the Market?

By type, cardiovascular catheters accounted for the largest share of the global market in 2024 and are expected to grow at the fastest rate through 2030.

What explains this dominance? The increasing incidence of cardiovascular diseases—including coronary artery disease, heart failure, and arrhythmias—particularly among aging populations, is significantly driving demand. These conditions often require catheter-based procedures such as angioplasty and ablation, making cardiovascular catheters indispensable in clinical practice.

Moreover, advancements in drug-eluting and imaging-compatible catheters have improved safety and procedural outcomes. Growing awareness of early cardiac intervention, coupled with favorable reimbursement policies, is further supporting adoption. Continuous R&D investments by leading manufacturers are also accelerating innovation and segment expansion.

Where Is the Fastest Growth by Indication?

The neurovascular conditions segment is projected to witness the highest CAGR during the forecast period.

How is this segment evolving? The rising prevalence of neurological disorders such as stroke, brain aneurysms, and arteriovenous malformations is increasing the need for catheter-based interventions. The adoption of minimally invasive neurovascular procedures—enabled by advancements in microcatheters, guidewires, and embolization technologies—is significantly boosting demand.

Improved awareness around early diagnosis and better stroke management outcomes is encouraging timely treatment, while the expansion of specialized stroke centers and neurointerventional teams is enhancing access to advanced therapies.

Why Is Asia Pacific Emerging as a Strategic Growth Region?

Asia Pacific is expected to register the highest growth rate in the global catheters market during the forecast period.

What factors are driving this regional surge? The rising prevalence of chronic diseases such as cardiovascular and kidney disorders, combined with a rapidly aging population, is creating strong demand for catheter-based procedures.

In addition, improving healthcare infrastructure, increased patient awareness, and growing government investments across countries such as China, India, and Japan are accelerating market expansion. The presence of local manufacturers offering cost-effective catheter solutions, along with the growing adoption of minimally invasive surgeries, further strengthens the region’s position as a high-growth market.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=6247803 

Strategic Market Landscape

Key players operating in the global catheters market include Boston Scientific Corporation, Medtronic PLC, B. Braun SE, Becton Dickinson and Company, Stryker Corporation, Abbott Laboratories, Terumo Corporation, Coloplast A/S, Convatec Group PLC, Merit Medical Systems, Johnson & Johnson Services, Inc., Cook, Edwards Lifesciences Corporation, Nipro Corporation, Teleflex Incorporated, Cardinal Health, Hollister Incorporated, Integra LifeSciences Corporation, Koninklijke Philips N.V., and MicroPort Scientific Corporation.

These companies are actively investing in product innovation, digital integration, and global expansion to strengthen their competitive positioning.

Why This Matters for Industry Leaders

For CEOs, medical device innovators, and healthcare investors, the catheters market represents a critical growth frontier shaped by rising clinical demand and rapid technological advancement.

What strategic priorities should leaders focus on? Investing in next-generation catheter technologies, expanding presence in high-growth regions like Asia Pacific, and aligning with the global shift toward minimally invasive care will be essential to capture long-term value.

As healthcare systems continue to evolve toward precision, efficiency, and patient-centricity, catheter-based solutions will remain central to delivering high-quality, scalable care.

Mice Model Market to Reach $2.74 Billion by 2030, Driven by CRISPR Advancements and Rising Demand for Precision Research

 The global Mice Model Market is projected to grow from USD 1.70 billion in 2025 to USD 2.74 billion by 2030, registering a CAGR of 10.0% during the forecast period. Growth is being fueled by increasing reliance on mice models in preclinical research, rising adoption of mouse clinical trials (MCTs), and expanding applications in personalized medicine—particularly in oncology.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308 

Market Drivers: Precision Medicine and Preclinical Innovation Take Center Stage

The growing use of mice models in biomedical research is driven by their genetic and physiological similarity to humans, making them highly effective for disease modeling and therapeutic validation. The rising emphasis on personalized medicine and targeted therapies is further accelerating demand for disease-specific and genetically engineered models.

Advancements in genetic engineering technologies, especially CRISPR-based genome editing, are significantly reducing development timelines and enabling more precise and scalable model generation—supporting faster drug discovery and translational research.

Model Type Insights: Inbred Mice Segment Leads the Market

By model type, the inbred mice segment accounted for the largest market share in 2024. These genetically identical (isogenic) models offer high reproducibility across experiments, making them essential for consistent research outcomes.

Inbred mice are widely used across pharmacology, oncology, cardiovascular studies, and behavioral research. Their ability to isolate genetic variables supports applications ranging from tumor biology and therapy response studies to vaccine and diagnostic validation.

Technology Trends: CRISPR/Cas9 Emerges as Dominant Innovation Driver

By technology, the CRISPR/Cas9 segment held the largest market share in 2024, driven by its precision, efficiency, and scalability in genome editing.

CRISPR enables targeted gene modifications at the embryonic stage, eliminating lengthy breeding cycles and significantly accelerating model development. Its ability to perform multiplex gene editing supports high-throughput in vivo screening, making it a preferred technology for research institutions and pharmaceutical companies.

Recent scientific advancements further highlight its impact, with large-scale gene knockout studies demonstrating its effectiveness in identifying novel therapeutic targets.

Regional Insights: North America Maintains Market Leadership

North America accounted for the largest share of the mice model market in 2024, supported by strong biomedical research infrastructure, regulatory frameworks, and high R&D investments.

The US leads the region, driven by a dense ecosystem of contract research organizations (CROs), academic institutions, and biotechnology firms. Major players continue to expand breeding capabilities and preclinical service offerings to meet growing demand.

Key companies operating in this space include:  Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), Biocytogen (China), Trans Genic Inc. (Japan) Harbour BioMed (China), genOway (France), GemPharmatech (China), Cyagen (US), Ozgene Pty Ltd (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Vivo Bio Tech Ltd (India), ingenious targeting laboratory (US), Janvier Labs (France), Champions Oncology, Inc (US), and Vitalstar Biotechnology Co., Ltd. (China), among others.

These organizations play a critical role in advancing genetically engineered models and supporting end-to-end preclinical research services.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1308 

Competitive Landscape: Expanding Capabilities Across Global Players

The market is highly competitive, with players focusing on expanding genetic engineering capabilities, improving breeding efficiency, and offering integrated preclinical solutions. Companies are also investing in CRISPR-based platforms and disease-specific model development to strengthen their market position.

Strategic Outlook: Growing Importance in Drug Discovery and Translational Research

As pharmaceutical and biotechnology companies accelerate drug development pipelines, the demand for reliable, scalable, and high-fidelity animal models will continue to rise.

The integration of advanced gene-editing technologies, increasing adoption of personalized medicine, and expansion of CRO-led research are expected to create significant growth opportunities in the global mice model market through 2030.

Next-Generation Sequencing Services Market to Reach $8.77 Billion by 2030, at a CAGR of 18.2%

 The global Next-Generation Sequencing (NGS) Services Market is projected to grow from USD 3.80 billion in 2025 to USD 8.77 billion by 2030, registering an impressive CAGR of 18.2% during the forecast period. The market is witnessing rapid expansion fueled by increasing demand for precision diagnostics, growing cancer incidence, and large-scale genomics programs worldwide.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194102241 

Market Dynamics: Precision Medicine and Population Genomics Drive Demand

The adoption of NGS services is accelerating across clinical and research settings due to the rising burden of cancer and rare diseases. Healthcare systems are increasingly relying on sequencing for faster, more accurate, and report-ready insights to support diagnosis and treatment decisions.

Declining sequencing costs have made large-scale genomic studies more accessible, while national genomics initiatives and population health programs are creating consistent demand for outsourced sequencing and downstream bioinformatics analysis. These trends are positioning NGS services as a cornerstone of modern precision medicine.

Service Insights: Sequencing Segment Maintains Market Leadership

By service type, sequencing services accounted for the largest share of the market in 2024. This dominance is largely driven by high-throughput project volumes across oncology, rare diseases, reproductive health, and infectious disease surveillance.

Service providers are increasingly scaling their capabilities to handle large datasets and deliver faster turnaround times, reinforcing sequencing as the core revenue-generating segment within the NGS services ecosystem.

Application Trends: Diagnostics Segment to Lead and Grow Fastest

By application, the diagnostics segment is expected to dominate the market and register the highest CAGR through 2030. Growth is being driven by expanding use cases in oncology, hereditary disease testing, and infectious disease detection.

The increasing adoption of tumor profiling and comprehensive genomic profiling (CGP), along with the rise of companion diagnostics linked to targeted therapies, is further strengthening demand for NGS-based diagnostic services.

Regional Outlook: Asia Pacific Emerges as High-Growth Hub

The Asia Pacific region is projected to witness the fastest growth during the forecast period, with China emerging as a key market driver.

Rapid expansion of clinical testing volumes, strong hospital and laboratory networks, and increased outsourcing of sequencing services are fueling regional growth. Additionally, the rise in biopharmaceutical R&D and genomics-driven clinical trials is generating sustained demand for sequencing and data analysis services.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=194102241 

Competitive Landscape: Leading Players Scale Capacity and Innovation

The NGS services market is highly competitive, with key players focusing on expanding sequencing capacity, enhancing bioinformatics capabilities, and strengthening global service networks. Prominent companies include:

• Illumina, Inc.

• Thermo Fisher Scientific

• Eurofins Scientific

These companies are investing in high-throughput sequencing platforms, advanced analytics, and integrated service offerings to support the growing demand for genomic insights across healthcare and research sectors.

Strategic Outlook: NGS Services at the Core of Future Healthcare

As healthcare transitions toward data-driven, personalized medicine, NGS services are becoming indispensable for diagnostics, drug development, and population health management.

Future growth will be driven by continued advancements in sequencing technologies, integration of AI in genomic analysis, and expansion of clinical applications. Organizations that can deliver scalable, fast, and clinically actionable sequencing solutions will be well-positioned to lead this rapidly evolving market.

Growing Demand for Precision Medicine Fuels Human Organoids Market to $2.33 Billion by 2029

 The global Human Organoids Market is gaining significant strategic traction as life sciences organizations accelerate the shift toward more predictive, ethical, and cost-efficient research models. Valued at USD 1.19 billion in 2024, the market is projected to reach USD 2.33 billion by 2029, growing at a CAGR of 14.4% during the forecast period. This growth underscores a critical transformation in drug discovery, disease modeling, and personalized medicine.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Browse

• 543     Market Data Tables
• 51       Figures
• 426     Pages and in-depth TOC on " Human Organoids Market  - Global Forecast to 2029”.

What is driving this rapid expansion, and why does it matter now?

The increasing need to reduce animal testing, combined with growing regulatory and public pressure for ethical research practices, is positioning organoids as a preferred alternative. These advanced 2D and 3D biological models replicate human organ functions more accurately, enabling pharmaceutical and biotechnology companies to generate highly reliable early-stage data.

How does this impact business outcomes? By improving predictive accuracy in drug development, organoids help organizations identify viable compounds earlier in the pipeline—reducing late-stage failures and significantly lowering R&D costs. This efficiency is particularly critical for CEOs and CFOs seeking to optimize innovation ROI while maintaining compliance with evolving regulatory standards.

Moreover, who is investing in this space? Both public and private sector stakeholders are increasing funding for organoid research, recognizing its transformative potential across oncology, gastrointestinal, and neurological disorders. When combined with the rising global burden of cancer and infectious diseases, the demand for advanced disease modeling tools continues to intensify.

Where are organoids making the greatest impact?

Beyond drug toxicity testing and disease modeling, applications are rapidly expanding into regenerative medicine, toxicology, and personalized therapies—unlocking new revenue streams and innovation pathways for industry players.

From a technology standpoint, the Matrigel matrix culture segment emerged as the dominant culture method in 2023. Why does this segment lead? Its ease of use, compatibility with diverse cell types, and ability to support organoid growth and differentiation across multiple organ systems—including liver, brain, and intestines—have made it a preferred choice among researchers. This widespread adoption reinforces its strong market position.

In terms of disease focus, the oncology segment accounted for the largest share in 2023. What explains this dominance? The rising global prevalence of cancer has intensified the need for highly accurate tumor models. Organoids enable researchers to replicate patient-specific tumor environments, facilitating precision medicine approaches. How does this benefit healthcare systems? It allows for tailored treatment strategies, improved efficacy, and reduced side effects—key priorities for clinicians and healthcare providers.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Where is the center of gravity for innovation and growth?

Regionally, North America leads the global human organoids market. Why is this region at the forefront? Advanced healthcare infrastructure, high healthcare expenditure, and strong investment in biomedical innovation—particularly in the US and Canada—are driving adoption. Additionally, the increasing incidence of cancer and infectious diseases in the region is fueling demand for advanced research tools.

Who are the key players shaping competition and innovation in this market?

Key industry players shaping this market include Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), HUB Organoids BV (Netherlands), BICO (Sweden), BeCytes Biotechnologies SL (Spain), InSphero (Switzerland), GBA Group (Germany), and Kirkstall Ltd. (UK). These companies are actively advancing organoid technologies to strengthen their competitive positioning and address evolving market needs. 

Healthcare Data Monetization Market to Reach $1.16 Billion by 2030

 The global Healthcare Data Monetization Market is projected to grow from USD 0.58 billion in 2025 to USD 1.16 billion by 2030, at a robust CAGR of 14.9% during the forecast period. Growth is being fueled by rapid healthcare digitalization, increasing data generation from connected ecosystems, and rising demand for data-driven decision-making.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=56622234 

Market Dynamics: Data Explosion and Value-Based Care Unlock New Revenue Streams

The healthcare industry is generating unprecedented volumes of data through electronic health records (EHRs), wearable devices, and connected health platforms. This surge is prompting stakeholders to explore monetization strategies that transform raw data into actionable insights and new revenue streams.

The shift toward value-based care is further accelerating adoption, as healthcare organizations seek to improve outcomes while optimizing costs. Data monetization enables better patient insights, operational efficiencies, and enhanced clinical decision-making—positioning it as a strategic priority across the ecosystem.

Segment Insights: Direct Monetization Leads Market Growth

By type, direct data monetization accounted for the largest share of the market in 2024. Healthcare organizations are increasingly leveraging data assets through licensing, partnerships, and analytics-driven services to generate immediate revenue.

Within this segment, software solutions are expected to dominate, driven by growing adoption of advanced analytics platforms, data integration tools, and secure data exchange systems. These solutions provide scalability, automation, and compliance capabilities essential for managing and commercializing large datasets.

Deployment Trends: Cloud Segment to Witness Highest Growth

The cloud deployment model is projected to grow at the highest CAGR during the forecast period. Its scalability, cost-effectiveness, and seamless integration capabilities make it ideal for handling large-scale healthcare data.

Recent innovations highlight this shift. Oracle Corporation introduced a next-generation cloud-based EHR platform enhanced with AI capabilities, while Salesforce, Inc. launched AI-powered healthcare tools to optimize patient care workflows. These developments underscore the growing reliance on cloud and AI technologies in healthcare data monetization.

Regional Outlook: North America Leads Global Adoption

North America accounted for the largest share of the healthcare data monetization market in 2024, supported by advanced digital infrastructure, strong regulatory frameworks, and high adoption of healthcare IT systems.

The region benefits from widespread use of EHRs, telehealth platforms, and connected devices, creating a strong foundation for data generation and monetization. The presence of major technology leaders such as Microsoft Corporation, IBM, and Google further accelerates innovation and deployment of advanced data solutions.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=56622234 

Competitive Landscape: Tech and Healthcare Players Drive Innovation

The healthcare data monetization market is highly competitive, with leading technology providers and healthcare IT companies focusing on AI, analytics, and interoperability solutions. Key players include: Oracle Corporation (US), Microsoft Corporation (US), Google (US), Salesforce, Inc. (US), SAS Institute Inc. (US), SAP SE (Germany), TIBCO Software Inc. (US), Sisense Inc. (US), Snowflake Inc. (US), QlikTech International AB (US), HealthVerity, Inc. (US), Accenture (Ireland), Availity, LLC (US), Domo, Inc. (US), Komodo Health, Inc. (US), ThoughtSpot Inc. (US), Datavant (US), Verato (US), Infor, Inc. (US), Virtusa (US), Infosys (India), Particle Health, Inc. (US), Innovaccer, Inc. (US), H1 (US), and Medable Inc. (US).

These companies are investing in secure data platforms, AI-driven analytics, and interoperability frameworks to unlock the full value of healthcare data.

Strategic Outlook: Data as a Core Healthcare Asset

As healthcare systems evolve, data is becoming a critical strategic asset. Organizations are increasingly leveraging monetization strategies not only for revenue generation but also to enhance patient outcomes and operational performance.

The convergence of AI, cloud computing, and interoperability standards will continue to drive innovation in this space. Companies that can ensure data security, compliance, and scalability will be best positioned to capitalize on the growing demand for healthcare data monetization.

 

IVD Reagents Market to Hit $87.41 Billion by 2029

 The report IVD Reagents Market by Type (Antibodies, Nucleic Acid Probes), technology (Hematology), Application (Genetic Testing, Autoimmune disease), Test Type (Laboratory Test, Point-of-care Tests), End User (Hospitals & Clinics) & Region - Global Forecast to 2029", is projected to reach 87.41 billion by 2029 from USD 60.45 billion in 2024, at a CAGR of 7.7% during the forecast period.

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131261429
 
Browse

• 536   Market Data Tables
• 59     Figures
• 423   Pages and in-depth TOC on " IVD Reagents Market - Global Forecast to 2029”.

Some of the prominent key players are:

• Danaher Corporation (US),
• F. Hoffmann-La Roche Ltd (Switzerland),
• Abbott (US),
• Siemens Healthineers AG (Germany),
• Thermo Fisher Scientific Inc. (US),
• Illumina, Inc. (US),
• BioMerieux (France), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the IVD Reagents Market.

Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131261429

• Based on type, the global IVD Reagents market is segmented into five categories namely, antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. Antibodies has led the IVD Reagents market.
• Based on technology segment this is the fastest growing segment, the IVD Reagents market is segmented into categories namely, immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, chromatography & mass spectrometry, and immunohistochemistry.
• Based on end users, the IVD reagents market is segmented into hospitals & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users. 
• The global IVD Reagents market is divided into six key regions: North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR of 10.0% in the IVD Reagents market during the forecast period.

In vitro diagnostic (IVD) reagents are chemicals or substances used to detect, measure, or produce a reaction with components of a sample in an IVD test. They are essential for accurately detecting biological markers or analytes in samples. The market growth is mainly due to growing burden of chronic diseases among aging population. In addition, increasing number of clinical laboratories providing in vitro diagnosis to offer growth opportunities for players operating in the IVD Reagents market during the forecast period. However, the stringent regulatory guidelines is expected to hamper the adoption of these products.

Immunotherapy Drugs Market to Surpass $580.6 Billion by 2029

 The global Immunotherapy Drugs Market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, registering a robust CAGR of 15.3% during the forecast period. The market is expanding rapidly, driven by technological advancements in antibody engineering, increasing adoption of personalized medicine, and rising demand for targeted cancer therapies.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755 

Market Dynamics: Innovation and Personalization Accelerate Adoption

The growing burden of cancer and chronic diseases is significantly boosting demand for immunotherapy drugs worldwide. Advances in monoclonal antibodies, checkpoint inhibitors, and cell-based therapies are transforming treatment paradigms—offering improved efficacy and reduced side effects compared to traditional therapies.

At the same time, increasing investment in R&D and strong clinical pipelines are accelerating innovation. However, stringent regulatory approval processes and the high cost of biologics—particularly monoclonal antibody therapies—remain key challenges for market growth.

Segment Insights: Antibody Drugs Lead Market Expansion

By type, antibody drugs are expected to maintain the largest market share throughout the forecast period. Growth in this segment is driven by rising cancer prevalence, increased adoption of biologics, and supportive government initiatives.

Monoclonal antibodies and checkpoint inhibitors continue to dominate due to their ability to precisely target disease pathways, improving patient outcomes and enabling more personalized treatment strategies.

Application Trends: Cancer Segment Dominates Market Demand

By application, the cancer segment accounted for the largest share and is expected to continue its dominance through 2029. Increasing global cancer incidence, coupled with growing adoption of immunotherapy as a frontline treatment, is fueling demand.

Pharmaceutical companies are intensifying efforts in clinical research, strategic collaborations, and therapy development to enhance immune system responses against tumors—bringing new hope to patients and reshaping oncology care.

Route of Administration: Intravenous Segment Leads and Grows Fastest

The intravenous (IV) route of administration held the largest share in 2023 and is projected to grow at the highest rate during the forecast period.

Its widespread use is attributed to rapid drug delivery, controlled dosing, and consistent therapeutic outcomes—particularly critical in oncology and autoimmune disease treatments.

End-User Insights: Hospitals Drive Market Revenue

By end user, hospitals generated the highest revenue in 2024. Their central role in administering complex therapies, conducting clinical trials, and delivering advanced patient care positions them as key stakeholders in the immunotherapy ecosystem.

Hospitals continue to adopt innovative therapies, supported by their infrastructure, clinical expertise, and focus on improving patient outcomes.

Regional Outlook: North America Maintains Market Leadership

North America is expected to dominate the global immunotherapy drugs market throughout the forecast period. The region benefits from a strong biopharmaceutical industry, high R&D investment, and increasing approval of immunotherapy drugs.

Rising cancer prevalence, expanding clinical trial activity, and rapid adoption of advanced therapies are further strengthening market growth across the region.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=137717755 

Competitive Landscape: Leading Pharma Giants Drive Innovation

The immunotherapy drugs market is highly competitive, with major pharmaceutical companies focusing on innovation, strategic collaborations, and expanding therapeutic pipelines. Key players include: Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland) emerging as top three players in the market. While Pfizer Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Amgen Inc. (US), Gilead Sciences, Inc. (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), GSK PLC (US), and Abbvie Inc. (US) are some of the other prominent players in the market.

These companies are investing heavily in next-generation immunotherapies, including combination treatments, cell and gene therapies, and novel biologics to strengthen their market positions.

Strategic Outlook: Immunotherapy at the Forefront of Next-Gen Medicine

Immunotherapy is rapidly emerging as a cornerstone of modern medicine, particularly in oncology and chronic disease management. The shift toward precision medicine, targeted therapies, and immune-based treatments is expected to redefine treatment standards globally.

With a strong pipeline, increasing regulatory approvals, and growing clinical adoption, the immunotherapy drugs market is poised for sustained high growth—offering significant opportunities for innovation and improved patient outcomes.

IVD Quality Control Market to Reach $2.15 Billion by 2030, Driven by Rising Lab Accreditation and EQA Demand

 The global In Vitro Diagnostics (IVD) Quality Control Market is projected to grow from USD 1.65 billion in 2025 to USD 2.15 billion by 2030, registering a CAGR of 5.5% during the forecast period. Market growth is being driven by the increasing number of accredited laboratories and the rising demand for external quality assessment (EQA) programs to ensure diagnostic accuracy and compliance.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582 

Market Dynamics: Accreditation and Quality Assurance Drive Adoption

The growing emphasis on laboratory accreditation from global regulatory bodies such as International Organization for Standardization, College of American Pathologists, and Clinical Laboratory Improvement Amendments is significantly boosting demand for robust IVD quality control solutions.

Laboratories are increasingly adopting advanced QC products and participating in EQA programs to ensure testing accuracy, reproducibility, and compliance. This shift is reinforcing the importance of independent quality assessment tools and driving sustained market expansion.

Segment Insights: Third-Party Controls Dominate the Market

By manufacturer type, third-party controls accounted for the largest share of the IVD quality controls market in 2024. Their widespread adoption is attributed to their compatibility across multiple instruments and reagent systems, offering laboratories greater flexibility and cost efficiency.

Unlike OEM controls, third-party solutions provide an independent and unbiased assessment of laboratory performance. Their longer shelf life, stable analyte composition, and clinically relevant ranges make them a preferred choice for laboratories seeking standardization and regulatory compliance.

End-User Trends: Clinical Laboratories to Witness Fastest Growth

By end user, clinical laboratories are expected to register the fastest growth during the forecast period. The increasing volume of diagnostic testing, particularly in specialized and independent labs, is driving demand for high-quality QC solutions.

These laboratories are prioritizing accuracy, reproducibility, and workflow efficiency—leading to increased adoption of multianalyte controls, automated QC systems, and data management solutions. The expansion of high-throughput testing further supports the need for scalable and reliable quality control systems.

Regional Outlook: North America Leads Global Market

North America holds the largest share of the IVD quality controls market, supported by advanced healthcare infrastructure, strong regulatory oversight, and high diagnostic testing volumes.

The region’s leadership is further reinforced by early adoption of automated and molecular diagnostic technologies, as well as a strong presence of leading industry players. Continuous investments in innovation and stringent quality standards ensure sustained demand for advanced QC solutions.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=198032582 

Competitive Landscape: Focus on Innovation and Compliance

The IVD quality controls market is highly competitive, with leading players focusing on expanding product portfolios, enhancing QC accuracy, and supporting regulatory compliance. Key companies include:  Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), Danaher Corporation (US), Sysmex Corporation (Japan), Bio-Techne Corporation (US), Microbix Biosystems Inc. (Canada), Microbiologics, Inc. (US), ZeptoMetrix (US), Fortress Diagnostics (UK), Helena Laboratories Corporation (US), Streck, Inc. (US), SERO AS (Norway), Maine Molecular Quality Controls, Inc. (US), Sun Diagnostics, LLC (US), Alpha-Tec (US), Grifols, S.A. (Spain), ConeBioproducts (US), Eurotrol B.V. (Netherlands), and Biorex Diagnostics (UK).

These companies are investing in advanced QC materials, digital quality management systems, and global distribution capabilities to meet the evolving needs of diagnostic laboratories.

Strategic Outlook: Quality Control as a Cornerstone of Diagnostic Excellence

As diagnostic testing becomes more complex and high-throughput, quality control is emerging as a critical pillar of laboratory operations. The shift toward automation, molecular diagnostics, and point-of-care testing is further increasing the need for reliable and scalable QC solutions.

Going forward, innovation in multianalyte controls, data integration, and real-time monitoring will shape the future of the market—ensuring improved diagnostic accuracy, regulatory compliance, and patient outcomes.

Biobanking Market to Reach $11.82 Billion by 2030

 The global Biobanking Market is projected to grow from USD 7.65 billion in 2025 to USD 11.82 billion by 2030, registering a CAGR of 9.1% during the forecast period. Market expansion is being driven by the increasing focus on precision medicine, a rapidly growing cell and gene therapy pipeline, and advancements in automated sample handling and storage technologies.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594 

Market Dynamics: Precision Medicine and Automation Reshape Biobanking

Biobanking is becoming a critical backbone of modern healthcare and life sciences research. The growing demand for personalized therapies and biologics is significantly increasing the need for high-quality biological sample storage and management.

End-to-end automation is transforming biobank operations—improving efficiency, reducing human error, and ensuring consistent sample integrity. At the same time, sustainability initiatives and green-lab solutions are emerging as key opportunities for innovation. However, long-term funding stability, particularly for public biobanks, remains a challenge for market stakeholders.

Product Insights: Equipment Segment Leads with Critical Storage Infrastructure

By product, the equipment segment accounted for the largest share of the biobanking market in 2024. Core infrastructure such as freezers, refrigerators, and cryogenic storage systems plays a vital role in preserving biological samples including blood, tissues, and DNA.

Ultra-low temperature freezers and cryogenic systems are especially critical for maintaining the viability of sensitive materials such as stem cells, cell lines, and nucleic acids over extended periods—making them indispensable in research, diagnostics, and therapeutic development workflows.

End-User Trends: Pharma, Biotech & CROs to Drive Fastest Growth

The pharmaceutical & biotechnology companies and contract research organizations (CROs) segment is expected to register the highest growth rate during the forecast period.

This growth is fueled by increasing demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies. These organizations rely heavily on biobanking services for clinical sample management, drug development, and large-scale research—driving adoption of advanced storage and data management solutions.

Regional Outlook: Asia Pacific Emerges as High-Growth Market

The Asia Pacific region is projected to register the highest CAGR during the forecast period. Countries such as China, India, and Japan are rapidly expanding their research infrastructure and healthcare capabilities.

Biobanks in the region are becoming essential for supporting drug discovery, clinical trials, and population health studies. Additionally, rising chronic disease prevalence and aging populations are increasing demand for comprehensive biobanking solutions to enable future healthcare innovations.

Sepak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=594 

Competitive Landscape: Innovation and Global Expansion Intensify Competition

The biobanking market is characterized by strong competition and continuous innovation, with leading players focusing on automation, advanced storage technologies, and integrated solutions. Key companies include: The key players in the biobanking market include Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Merck KGaA (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), and Cryoport (US), among other players.

These companies are investing in scalable, automated, and sustainable biobanking solutions to meet the growing global demand for high-quality biological sample management.

Strategic Outlook: Biobanking at the Core of Next-Generation Healthcare

As life sciences shift toward precision medicine, regenerative therapies, and data-driven research, biobanking is becoming increasingly central to innovation.

Future growth will be shaped by advancements in automation, integration with digital platforms, and sustainable lab practices. Organizations that can deliver scalable, compliant, and high-integrity biobanking solutions will be well-positioned to capitalize on this expanding market.

Global Infusion Pump Market Expected to Grow to $28.3 Billion by 2030

 The report "Infusion Pump Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Insulin, Syringe, Volumetric, Enteral, PCA Pump)), Technology (Traditional, Specialty), Mode (Stationary, Portable), Application (Cancer, Diabetes) - Global Forecast to 2030", is projected to reach USD 28.3 billion by 2030 from USD 19.9 billion in 2025, growing at a CAGR of 7.4%.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=90374506
 
Browse

• 608   Market Data Tables
• 86     Figures
• 582   Pages and in-depth TOC on " Infusion Pump Market - Global Forecast to 2030”

Some of the prominent key players are:

• Becton, Dickinson and Company (US),
• Baxter International Inc. (US),
• B. Braun Melsungen AG (Germany),
• Terumo Corporation (Japan),
• NIPRO (Japan),
• Fresenius Kabi (Germany), 
• ICU Medical, Inc. (US). and many more.......

 

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Infusion Pump Market.

Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=90374506

• Based on products, The devices segment of the infusion pump market held the largest share in 2024 because infusion pumps are widely used in hospitals, clinics, and homecare for precise and controlled drug delivery. The rise in chronic diseases, more surgical procedures, and the increasing adoption of advanced, smart, and portable pumps have further boosted demand.
• Based on type, the accessories & consumables segment accounted for a larger market share in 2024. The substantial market share attributed to infusion pump disposables is primarily linked to their critical role in ensuring safe and effective medication administration through recurrent use. This category encompasses essential components such as infusion sets, catheters, tubing, and connectors, all of which are single-use items that require regular replacement to maintain patient safety and minimize infection risk.
• Based on applications, The rapid expansion of the diabetes management segment is primarily driven by the increasing prevalence of diabetes, alongside significant technological advancements in infusion pump devices, notably insulin pumps. A key factor propelling this segment forward is the emergence of sophisticated insulin delivery systems, specifically hybrid closed-loop systems, commonly referred to as artificial pancreas devices.
• Geographically, the infusion pumps market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa. In 2024, North America emerged as the dominant player in the infusion pump market, primarily driven by substantial healthcare expenditures in the US.

Infusion pumps are medical devices used to deliver controlled amounts of fluids, such as nutrients and medications, into a patient’s body. The market growth is driven by the rising prevalence of chronic diseases such as diabetes and cancer, increasing demand for advanced drug delivery systems, and growing adoption of ambulatory and homecare settings. Furthermore, technological advancements in smart infusion systems and supportive regulatory frameworks promoting patient safety are expected to boost market expansion during the forecast period.

 

The market is expected to experience significant growth over the next decade, driven by increasing healthcare demands, technological progress, and the rising need for precise drug delivery systems. Infusion pumps are being adopted more widely because of their ability to deliver controlled and accurate doses, making them essential for managing chronic diseases, oncology treatments, and pain management. The move toward home healthcare, along with the integration of smart, connected pump technologies, further boosts their importance in enhancing patient safety and treatment results. With a growing global patient population and a focus on advanced care solutions, infusion pumps are poised to play a key role in modern healthcare delivery.